Overview

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
0
Participant gender:
All
Summary
This is a study of the safety, tolerability, pharmacokinetics (measurement of drug levels in the blood), and intraocular pressure lowering effects of OPA-6566 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Acucela Inc.
Kubota Vision Inc.
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Latanoprost
Ophthalmic Solutions
Criteria
Inclusion Criteria:

- diagnosis of bilateral primary open-angle glaucoma

- diagnosis of ocular hypertension as defined in the protocol

Exclusion Criteria:

- any form of glaucoma other than primary open-angle glaucoma in either eye

- other ocular conditions as defined by the protocol